• Flanders Investment & Trade
  • Team Vesalius

Baron Peter Carmeliet, MD, PhD (KU Leuven- one of Flanders’ five universities) is head of the Laboratory of Angiogenesis & Vascular Metabolism and former director of the VIB-KU Leuven Center for Cancer Biology.

Peter Carmeliet

VIB - KU Leuven

Oude Markt 13
3000 Leuven

His groundbreaking work in angiogenesis, the study of the growth and function of blood vessels in health and disease, has resulted in hundreds of published articles that are cited by colleagues across the globe, as well as several patents, and formed the basis of three spin-off companies and two (ongoing) clinical trials.

Through his career, he received numerous awards and decorations for his pioneering biomedical research and recently was elected as an International Honorary Member of the prestigious American Academy of Arts & Sciences (AAAS).

Team Vesalius visionairies

Flanders’ life sciences industry: the perfect combo of biotech, medtech, pharma and healthcare

Defining Flanders’ life sciences industry as diverse is an understatement. From young start-ups to established local firms and multinationals: the entire value chain – from research and discovery to development and commercialization – is represented in Belgium’s northern region. Thanks to fertile cross-pollination between biotech, medtech, pharmaceuticals and healthcare, Flanders offers a unique life sciences ecosystem that is underpinned by a robust financing landscape and a supportive government. Will your company claim its place in this dynamic hub?